

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Leuven, BELGIUM – September 8, 2025 – 06:00 PM CET - [Oxurion NV](#) (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notification as follows:

Oxurion received a transparency notification on September 3, 2025, from Atlas Special Opportunities II, LLC indicating that as of August 28, 2025, it held 4,003,999 shares of the then outstanding 50,377,523 shares, and therefore crossed under the threshold (10%) by virtue of the selling of voting securities.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) is a company specializing in acquiring majority stakes in promising European pharmaceutical subcontractors. Oxurion's ambition is to build an integrated group of subcontractors serving healthcare players. The Group's headquarters are based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

Additional Disclaimer

The planned investment in digital assets (such as Bitcoin and Ethereum) exposes the company to specific risks related to volatility, regulatory uncertainty, and cybersecurity. These factors may significantly affect the expected performance of the investments.

For further information please contact:

<p>Oxurion NV Pascal Ghoson Chief Executive Officer Pascal.ghoson@oxurion.com</p>

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
--	--

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights



4) Notification by

A person that notifies alone



5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577



6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)



Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

28/08/2025 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

10

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

50,377,623

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	6,677,305	4,003,999		7.95%	
TOTAL		4,003,999	0	7.95%	0.00%



Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	CALCULATE	4,003,999
		7.95%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information

On 13 August 2025 (with settlement date on 15 August 2025), Atlas Special Opportunities II LLC sold 2,426,132 shares in Oxurion NV, as a result of which its shareholding decreased to 6,677,305 shares (= 13.2545%, denominator = 50,377,523)
On 14 August 2025 (with settlement date on 18 August 2025), Atlas Special Opportunities II LLC sold 254,121 shares in Oxurion NV, as a result of which its shareholding decreased to 6,423,184 shares (= 12.7500%, denominator = 50,377,523)
On 15 August 2025 (with settlement date on 19 August 2025), Atlas Special Opportunities II LLC sold 205,027 shares in Oxurion NV, as a result of which its shareholding decreased to 6,218,157 share 12.34311%, denominator = 50,377,523)
On 18 August 2025 (with settlement date on 20 August 2025), Atlas Special Opportunities II LLC sold 63,541 shares in Oxurion NV, as a result of which its shareholding decreased to 6,154,616 shares (= 12.2169%, denominator = 50,377,523)
On 19 August 2025 (with settlement date on 21 August 2025), Atlas Special Opportunities II LLC sold 174,432 shares in Oxurion NV, as a result of which its shareholding decreased to 5,980,184 shares (= 11.8707%, denominator = 50,377,523)
On 20 August 2025 (with settlement date on 22 August 2025), Atlas Special Opportunities II LLC sold 155,327 shares in Oxurion NV, as a result of which its shareholding decreased to 5,824,857 shares (= 11.5624%, denominator = 50,377,523)
On 21 August 2025 (with settlement date on 25 August 2025), Atlas Special Opportunities II LLC sold 23,362 shares in Oxurion NV, as a result of which its shareholding decreased to 5,801,495 shares (= 11.5160%, denominator = 50,377,523)
On 22 August 2025 (with settlement date on 26 August 2025), Atlas Special Opportunities II LLC sold 122,091 shares in Oxurion NV, as a result of which its shareholding decreased to 5,679,404 shares (= 11.2736%, denominator = 50,377,523)
On 25 August 2025 (with settlement date on 27 August 2025), Atlas Special Opportunities II LLC sold 612,313 shares in Oxurion NV, as a result of which its shareholding decreased to 5,067,091 shares (= 10.0582%, denominator = 50,377,523)
On 26 August 2025 (with settlement date on 28 August 2025), Atlas Special Opportunities II LLC sold 1,063,092 shares in Oxurion NV, as a result of which its shareholding decreased to 4,003,999 shares (= 7.94798%, denominator = 50,377,523)

Done at New York

On 29/08/2025 (DD/MM/YYYY)

Name & capacity Patrick Vance, Proxyholder

Signed by:
Signature Patrick Vance
9A8C4789B05442E...

For security reasons, the unsigned form in **xlsx** format should